SCHEMBL3338690

SCHEMBL3338690

O=C(NNc1nc(-c2ccc3ccccc3c2)cs1)c1cc2ccccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.55
NPC1 O15118 3/20 0.55
GSTO1 P78417 1/20 0.52
AR P10275 1/20 0.51
KDM4E B2RXH2 9/20 0.51
MAPT P10636 9/20 0.51
GAA P10253 7/20 0.51
MEN1 O00255 7/20 0.51
KMT2A Q03164 7/20 0.51
ALDH1A1 P00352 4/20 0.51
LMNA P02545 4/20 0.51
PTGES O14684 1/20 0.51
HPGD P15428 1/20 0.51
VCP P55072 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CSNK2A1 P68400 3/20 0.50
HTT P42858 4/20 0.49
TDP1 Q9NUW8 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPK1 P28482 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3337375 0.90 MAPT (0.61) RAB9ANPC1KDM4EMAPTGAA
SCHEMBL3341337 0.88 MAPT (0.58) KDM4EMAPTGAAMEN1KMT2A
SCHEMBL3343759 0.85 KDM4E (0.67) RAB9AKDM4EMAPTGAAMEN1
SCHEMBL3339390 0.83 GAA (0.47) RAB9ANPC1KDM4EMAPTGAA
SCHEMBL3338990 0.83 CA12 (0.48) RAB9ANPC1KDM4EMAPTGAA
SCHEMBL3344530 0.82 GAA (0.46) RAB9ANPC1KDM4EMAPTGAA
SCHEMBL7894167 0.77 LMNA (0.58) RAB9ANPC1GSTO1KDM4EMAPT
SCHEMBL7894108 0.77 ADORA3 (0.66) RAB9ANPC1GSTO1KDM4EMAPT
SCHEMBL3341387 0.76 MAPT (0.60) RAB9ANPC1GSTO1ARKDM4E
SCHEMBL3342095 0.75 CNR2 (0.47) RAB9ANPC1KDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA RAB9A 2591/4885NPC1 36/4885GSTO1 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.